Program
14:00 – 14:10
WELCOME ADDRESS
14:10 – 15:50
SESSION 1: REAL-WORLD EXPERIENCE, NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES
KEYNOTE LECTURE
TBC
RWE: BEYOND CRS AND ICANS: HEMATOTOXICITY AND INFECTIONS AS DRIVERS OF CAR-T NRM
Marion Subklewe, LETSimmun Consortium, Germany
CLINICAL LEARNINGS AND NEW FRONTIERS FOR B CELL-DRIVEN DISEASES
Jennifer Brogdon, Novartis, USA
Panel discussion
15:50 – 16:30
COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS & POSTER VIEWING
16:30 – 18:15
SESSION 2: SUPERPOWERED LYMPHOCYTES
A PRIVATE CROSSTALK ESTABLISHED BY TUMOR-TARGETED CYTOKINE RELEASE RESCUES CAR T ACTIVITY AND ENGAGES HOST T-CELLS AGAINST GLIOBLASTOMA
Luigi Naldini, San Raffaele Telethon Institute for Gene Therapy, Italy
ENGINEERING T-CELLS FOR SUPERIOR PERFORMANCE
George Coukos, Ludwig Cancer Research Lausanne Branch, Switzerland
OVERCOMING T-CELL SENESCENCE BY GENOME EDITING
Chiara Bonini, Vita-Salute San Raffaele University, Italy
STAB-T-CELLS SECRETING ANTI-BCMA T-CELL ENGAGERS DEMONSTRATE SUPERIOR ANTITUMOR ACTIVITY COMPARED TO ANTI-BCMA CAR T-CELLS
Javier Arroyo-Rodenas, University Hospital October 12, Spain
T CELL-MEDIATED ADCC AS A THERAPEUTIC STRATEGY FOR SOLID CANCERS
Yaron Carmi, Tel Aviv University, Israel
ADDRESSING TUMOUR MICROENVIRONMENT RESISTANCE MECHANISMS TO IMPROVE CAR T-CELL EFFICACY
Paul Neeson, Peter MacCallum Cancer Centre, Australia
TBC
Panel discussion
18:15 – 19:45
MEET THE POSTER PRESENTERS & WELCOME RECEPTION
09:00 – 10:10
SESSION 3: NON-VIRAL CAR/TCR GENE TARGETING
CAR-TS GOING NON-VIRAL FROM BENCH TO BEDSIDE (AND BACK)
Michael Hudecek, LETSimmun Consortium, Germany
TBC
Panel Discussion
10:10 – 10:50
COFFEE BREAK, EXHIBITION, INDUSTRY PRESENTATIONS & POSTER VIEWING
10:50 – 12:20
SESSION 4: CUTTING-EDGE INDUSTRY ADVANCEMENTS
AUTOMATED, SCALABLE IMMUNE CELL CIRCULATION PLATFORM FOR CANCER MODELS
Mark Lyons, Hooke Bio, Ireland
TBC
Panel Discussion
12:20 – 13:50
LUNCH BREAK, TOP 10 POSTER PRESENTATIONS, EXHIBITION & POSTER VIEWING
13:50 – 15:15
SESSION 5: CAR/TCR MRNA THERAPIES
KEYNOTE LECTURE: NUCLEOSIDE-MODIFIED mRNA-LNP THERAPEUTICS
Drew Weissman, University of Pennsylvania School of Medicine, USA
MRNA-BASED T-CELL ENGINEERING FOR VIRUS-RELATED CANCERS (HBV-HCC) AND VIRAL INFECTIONS
Antonio Bartoletti, A*STAR, Singapore
ANTIGEN-SPECIFIC AND BYSTANDER ANTITUMOR ACTIVITY OF RNA CAR T-CELLS AGAINST GBM-ASSOCIATED ANTIGEN PTPRZ1
Darel Martínez Bedoya, University of Geneva, Switzerland
TBC
Panel Discussion
15:15 – 15:25
SHORT BREAK
15:25 – 16:35
SESSION 6: UNIVERSAL DONOR CELLS & ADVANCED TCR ENGINEERING
TARGETING CANCER WITH T-CELL RECEPTOR-ENGINEERED T-CELLS
Johanna Olweus, Oslo University, Norway
Dirk Busch, Technical University of Munich, Germany
DISRUPTED KINASE (DISK) CAR T-CELLS FOR ALLOGENEIC THERAPY
Previtha Dawn Sakthi Vale, National University of Singapore, Singapore
TBC
Panel Discussion
16:35 – 17:30
ENGAGE & ENERGIZE: NETWORKING AND INSPIRATIONAL BREAK
17:30 – 19:10
SESSION 7: UPDATED CLINICAL DATA
KEYNOTE LECTURE: CAR T-CELLS – CURRENT STATUS AND OUTLOOK
Carl June, University of Pennsylvania, USA
CONQUERING RESISTANCE MECHANISMS IN ENGINEERED CELL THERAPIES
Stan Riddel, Fred Hutchinson Cancer Research Center, USA
ALLOREACTIVE VERSUS IL-15 EX-VIVO-STIMULATED NK CELLS AS ADOPTIVE CELL THERAPY IN HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC ACUTE LEUKEMIA: A PHASE I/II TRIAL (PHINK)
Carmen Mestre-Durán, Research Institute of the University Hospital La Paz (IdiPAZ), Spain
TBC
Panel discussion
08:30 – 09:30
SESSION 8: BEYOND ALPHA-BETA T-CELLS
FROM AUTOLOGOUS TO ALLOGENEIC CAR EFFECTOR CELLS: PUSHING THE BOUNDARIES FROM CANCER TO OTHER SEVERE DISEASES
Ulrike Kohl, Fraunhofer Institute for Cell Therapy and Immunology Leipzig, Germany
REPROGRAMING IMMUNOSUPPRESSIVE MICROENVIRONMENT IN THE SOLID TUMOR BY TARGETED DELIVERY OF TGF-Β-BLOCKING SCFV FROM ANTIBODY-CAR-MACROPHAGES (AB-CAR-M)
Rio Sugimura, Hong Kong University, Hong Kong
TBC
Panel discussion
09:30 – 11:05
SESSION 9: TARGETING NON-MALIGNANT DISEASES
CAR T-CELL TREATMENT IN AUTOIMMUNE DISEASE
Georg Schett, Friedrich-Alexander University of Erlangen-Nuremberg, Germany
CAR T-CELLS AGAINST IgE B CELLS
Adi Barzel, Tel Aviv University, Israel
MODIFICATION OF TCR/CD3 TO ENHANCE T-CELL FUNCTION
Hans Stauss, University College London, UK
BASE EDITING OF APDS1 AND APDS2 T-CELLS RESTORES PI3K DELTA SIGNALLING
Kate Orf, UCL, United Kingdom
TBC
Panel discussion
11:05 – 11:40
COFFEE BREAK, EXHIBITION & POSTER PRESENTATIONS
11:40 – 12:40
SESSION 10: SELECTED ABSTRACTS FOR ORAL PRESENTATION
RAPID MACHINE LEARNING DRIVEN TARGET IDENTIFICATION IN TIL AND PERSONALISED TRANSGENIC TCR CELL THERAPIES
Edward Green, DKFZ, Germany
OVERCOMING BARRIERS FOR T-CELL THERAPY OF CHRONIC HEPATITIS B VIRUS INFECTION
Lisa Schiller, Technical University of Munich, Germany
SYSTEMIC DELIVERY OF CDH17 CAR T-CELLS ALLOWS EFFECTIVE AND SAFE TARGETING OF COLORECTAL CANCER LIVER METASTASES
Rita El Khoury, IRCCS San Raffaele Scientific Institute, Italy
DUAL TARGETING OF PD-L1 AND ERBB2 BY CAR-NK CELLS ENABLES SPECIFIC ELIMINATION OF SOLID TUMOR CELLS AND OVERCOMES IMMUNE ESCAPE VIA ANTIGEN LOSS
Jiri Eitler, Technical University of Dresden, Germany
TBC
Panel Discussion
12:40 – 13:40
SESSION 11: IN VIVO AND BEDSIDE T-CELL ENGINEERING
T-CELL TARGETED VECTORS FOR IN VIVO CAR DELIVERY
Christian Buchholz, PEI, Germany
EXTRACORPOREAL CAR GENE DELIVERY
David Peritt, Lupagen, USA
NOVEL NON-VIRAL DNA-BASED GENE THERAPY VECTOR FOR CAR T ENGINEERING IN VIVO
Jacek Lubelski, NanoCell, Netherlands
TBC
Panel Discussion
13:40 – 14:00
BEST POSTER ANNOUNCEMENT & CONFERENCE CLOSURE
Moderators: Adi Barzel, Tel-Aviv University, Israel
Dirk Busch, Technical University of Munich, Germany